Aaa Usa Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AAA USA INC, and what generic alternatives to AAA USA INC drugs are available?
AAA USA INC has two approved drugs.
There are four US patents protecting AAA USA INC drugs.
There are sixty-seven patent family members on AAA USA INC drugs in twenty-four countries and five supplementary protection certificates in five countries.
Summary for Aaa Usa Inc
| International Patents: | 67 |
| US Patents: | 4 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Aaa Usa Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aaa Usa Inc | LUTATHERA | lutetium lu 177 dotatate | SOLUTION;INTRAVENOUS | 208700-001 | Jan 26, 2018 | RX | Yes | Yes | 11,904,027*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Aaa Usa Inc | LUTATHERA | lutetium lu 177 dotatate | SOLUTION;INTRAVENOUS | 208700-001 | Jan 26, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Aaa Usa Inc | NETSPOT | gallium dotatate ga-68 | POWDER;INTRAVENOUS | 208547-001 | Jun 1, 2016 | RX | Yes | Yes | 9,375,498 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Aaa Usa Inc | LUTATHERA | lutetium lu 177 dotatate | SOLUTION;INTRAVENOUS | 208700-001 | Jan 26, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Aaa Usa Inc | LUTATHERA | lutetium lu 177 dotatate | SOLUTION;INTRAVENOUS | 208700-001 | Jan 26, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Aaa Usa Inc | LUTATHERA | lutetium lu 177 dotatate | SOLUTION;INTRAVENOUS | 208700-001 | Jan 26, 2018 | RX | Yes | Yes | 10,596,276*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Aaa Usa Inc | LUTATHERA | lutetium lu 177 dotatate | SOLUTION;INTRAVENOUS | 208700-001 | Jan 26, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Aaa Usa Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3826686 | ⤷ Subscribe |
| Israel | 275979 | ⤷ Subscribe |
| Japan | 2014524423 | ⤷ Subscribe |
| China | 103889930 | ⤷ Subscribe |
| Germany | 202018006567 | ⤷ Subscribe |
| Australia | 2022203683 | ⤷ Subscribe |
| Israel | 245849 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Aaa Usa Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 4095130 | 2024C/528 | Belgium | ⤷ Subscribe | PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; AUTHORISATION NUMBER AND DATE: EU/1/22/1703 20221212 |
| 4095130 | 122024000038 | Germany | ⤷ Subscribe | PRODUCT NAME: (177LU)LUTETIUMVIPIVOTIDTETRAXETAN; REGISTRATION NO/DATE: EU/1/22/1703 20221209 |
| 4095130 | CA 2024 00027 | Denmark | ⤷ Subscribe | PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDETETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212 |
| 4095130 | 301281 | Netherlands | ⤷ Subscribe | PRODUCT NAME: LUTETIUM (177-LU)-VIPIVOTIDE TETRAXETAN; REGISTRATION NO/DATE: EU/1/22/1703, 20221212 |
| 4095130 | LUC00352 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; AUTHORISATION NUMBER AND DATE: EU/1/22/1703 20221212 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
